Our CEO Poul Sørensen shared our latest progress this morning at RNA Leaders in Vienna
#RNATherapeutics #Pseudoexon #Parkinsons #Huntingtons #RNAleaders

Huntington’s disease is the best investment in neuroscience today Huntington’s disease (HD) is usually described as rare, tragic, and intractable. Yet, HD offers a strategically unique entry point for neuroscience. W…

Huntington’s disease is the best investment in neuroscience today www.sciencedirect.com/science/arti...
#Huntingtons #Neuroscience #Investment

Inverna Therapeutics announces the formation of its Scientific Advisory Board consisting of world-renowned leaders in RNA therapeutics and neurodegenerative research | Inverna Therapeutics Inverna Therapeutics is delighted to announce the formation of our new Scientific Advisory Board (SAB)🚀 We welcome world-renowned leaders in RNA therapeutics and neurodegenerative research to advance...

Exciting news from Inverna ! 🎉

www.linkedin.com/posts/invern...
#RNATherapeutics #Pseudoexon #ASO #Innovation

#invernatherapeutics #mjff #grant #parkinsonsdisease #lrrk2 #biotech #startup #neuroscience #innovation | Inverna Therapeutics 🎉 Exciting news from Inverna Therapeutics! 🚀 We’re honored to announce that Inverna has been awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) as part of the LRRK2 Inv...

Big news today! 🎉
#MJFF #RNAtherapeutics #Parkinsondisease #RNAsplicingmodulation #Pseudoexon #Innovation

@thepou1.bsky.social

🌟 Inverna is heading to San Francisco! 🌟 We’re thrilled to announce that Inverna and our CEO, Poul Sørensen, will be attending the annual JPM Week, one of the most prestigious events in the biotech and healthcare industry. This marks an exciting opportunity for Inverna to share our vision and connect with industry leaders, innovators, and collaborators. As we continue our work in developing disease-modifying therapeutics for Huntington’s disease through our novel RNA splicing modulation platform, we are eager to engage with those who share our passion for groundbreaking science. 📅 If you’re attending the conference and would like to discuss partnerships, innovation, or simply learn more about our journey, we’d love to meet you! Let’s build the future of biotech together.

🌟 Inverna is heading to JPM Week in SF! 🌟
Our CEO, Poul Sørensen, will share our vision for disease-modifying therapies for Huntington’s disease, powered by our RNA splicing platform.
📅 Attending too? Let’s connect to discuss partnerships and innovation!

#jpm2025 #biotech #huntington #rnasplicing

@thepou1.bsky.social

@invernatx.com

Press release for Inverna Therapeutics, a novel Danish biotech company at the forefront of innovative RNA therapeutics, today announced its launch as a leading-edge RNA therapeutics company. The Company was co-founded by the University of Southern Denmark and Argobio and is dedicated to transforming patient outcomes in severe genetic diseases, starting with a lead program addressing Huntington’s disease. Inverna’s platform originates from the groundbreaking research of Professor Brage Storstein Andresen, an internationally renowned expert in RNA splicing and antisense technology. Inverna aims to overcome the limitations of conventional RNA therapeutics by harnessing the revolutionary potential of sequence-based splice modulation to provide safer and more effective treatments for a wide range of debilitating diseases.

Introducing Inverna Therapeutics, a next-gen RNA splicing platform tackling severe genetic diseases, starting with Huntington’s disease.
Emerging from @argobiostudio.com and @sdu.dk, we're pioneering safer, more effective treatments for high unmet medical needs.
www.argobiostudio.com/en/news/next...